CFM
ROIV icon

Catalyst Funds Management’s Roivant Sciences ROIV Stock Holding History

Catalyst Funds Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
29,072
+4,041
+16% +$119K 0.06% 289
2026
Q1 		$693K Buy
+25,031
New +$643K 0.12% 200
2025
Q2 		– Sell
-23,440
Closed -$237K – 665
2025
Q1 		$237K Buy
+23,440
New +$253K 0.06% 313
2024
Q3 		– Sell
-1,000
Closed -$10.6K – 1566
2024
Q2 		$10.6K Sell
1,000
-338,800
-100% -$3.71M ﹤0.01% 903
2024
Q1 		$3.58M Buy
+339,800
New +$3.66M 1% 20

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Catalyst Funds Management's ROIV Position: Q2 2026 in Review

Catalyst Funds Management increased its Roivant Sciences (ROIV) stake by 16% in Q2 2026, buying an estimated $119K and bringing the position to 29,072 shares worth $1.03M. The position accounts for 0.06% of the portfolio, ranked #289.

Catalyst Funds Management first reported a position in ROIV in Q1 2024 and has held it in 5 quarters since. The position peaked at $3.58M in Q1 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Catalyst Funds Management held 29,072 shares of Roivant Sciences worth $1.03M as of Q2 2026.
  • Catalyst Funds Management bought 4,041 Roivant Sciences shares in Q2 2026, an estimated $119K.
  • Roivant Sciences made up 0.06% of Catalyst Funds Management's portfolio in Q2 2026, its #289 holding.
  • Catalyst Funds Management first reported a position in Roivant Sciences in Q1 2024 and has held it in 5 quarters since.
  • Catalyst Funds Management's Roivant Sciences position peaked at $3.58M in Q1 2024.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.